+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy



Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy



Antiviral Therapy 3(2): 81-88



Drug resistance patterns and their correlation to treatment response 24 weeks after addition of lamivudine to a previous zidovudine/zalcitabine or zidovudine/didanosine combination treatment, or after substitution of lamivudine for the zalcitabine or didanosine in these combinations, were evaluated in 21 patients with CD4+ cell counts between 50 and 300 cells/mmsuperscript 3. Clinical, immunological and virological outcomes were measured at baseline and at weeks 4, 12 and 24.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 003134532

Download citation: RISBibTeXText


Related references

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276(2): 111-117, 1996

Emergence of dual resistance to zidovudine and lamivudine in clinical HIV-1 isolates from patients receiving zidovudine/lamivudine combination therapy. Antiviral Therapy 3(2): 97-102, 1998

Retrospective study of zidovudine or didanosine monotherapy or zalcitabine plus zidovudine combination therapy in patients with early AIDS. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD [Author] Tenth International Conference on AIDS and the International Conference on STD, Vol 1; The global challenge of AIDS: Together for the future : 1) 209, 1994

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: A randomized controlled comparison with zidovudine monotherapy. JAMA (Journal of the American Medical Association) 276(2): 111-117, 1996

A six months follow-up randomized controlled trial of lamivudine combined with zidovudine vs lamivudine plus zidovudine plus zalcitabine or didanosine in HIV-1 infection and CD4+ cell count between 50-300/mu-L. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 206, 1996

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. Reviews in Medical Virology 4(1): 5-8, 1994

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. Reviews in Medical Virology 4(1): 9-12, 1994

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases 173(6): 1354-1366, 1996

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. Aids Research and Human Retroviruses 16(14): 1337-1344, 2000

A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215. Journal of Clinical Virology 19(3): 135-142, 2000

Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. Aids 12(4): 439-440, 1998

Drug resistance and viral load in NUCA 3002 Lamivudine /zidovudine combination therapy versus ZDV/dideoxycytidine combination therapy in ZDV-experienced patients. INFECTIOUS DISEASES SOCIETY OF AMERICA , NATIONAL INSTITUTES OF HEALTH , CENTERS FOR DISEASE CONTROL AND PREVENTION 3rd Conference on retroviruses and opportunistic infections : 113, 1996

Drug resistance and viral load in NUCA 3002 A comparative trial of lamivudine /zidovudine combination therapy vs ZDV/dideoxycytidine combination therapy in ZDV-experienced patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 10(Suppl. 3): S27, 1995

Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Medicine 5(1): 11-14, 2004

Acquisition of genotypic drug resistance in zidovudine -experienced patients receiving 3TC/ZDV combination therapy or ZDV monotherapy. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 10(Suppl. 3): S28, 1995